Table 1.

Published studies of the effect of obesity on breast cancer prognosis in premenopausal women

Author/year publishedPatient sourceReference BMINo. womenMedian follow-up (y)Association found?*Result: HR
DFS, HR (95% CI)OS, HR (95% CI)
Berclaz, 2004 (6)Trials≥30 versus <253,49414Yes1.16 (1.02-1.33)1.22 (1.05-1.42)
Dignam, 2003 (7)Trial≥30 versus <251,03513.8NoNRNR
Daling, 2001 (8)Population based>25.8 versus ≤201,177NRYesNR1.7 (1.0-2.9)
Hebert, 1998 (9)HospitalN/A2228-10Yes1.09 (1.02-1.17§)1.12 (1.03-1.22§)
Lethaby, 1996 (10)Population based≥28 versus <2827510.2NoNRNR
Holmberg, 1994 (11)Mixed≥29 versus <19422NRYes5.9 (2.0-17.8)NR
Jain, 1994 (12)Population based>27 versus <223635.2NoNR0.96 (0.90-1.03)
Kamby, 1989 (13)Population based≥24 versus <245434.9NoNRNR
Greenberg, 1985 (14)Hospital≥27 versus ≤20582NRNoNR1.8 (0.87-3.7**)
Mohle-Boetani, 1988 (15)Population based<30.5 versus ≥30.52266NoNR1.6 (0.94-2.7**)
  • Abbreviations: OS, overall survival; DFS, disease-free survival; NS, not significant; NR, not reported; N/A, not applicable because BMI analyzed as a continuous variable.

  • * Yes means statistically significant.

  • Patients from International Breast Cancer Study Group trials 1-IV, V, and VI-VII.

  • All node-negative, hormone receptor–positive tumors treated with tamoxifen or placebo (NSABP-B14).

  • § HR for each kg/m2 gained.

  • All node negative early breast cancers.

  • Swedish group: population based, Norwegian group: hospital based.

  • ** 95% CI not given but was calculated using estimate and P and assuming a log-normal distribution.